Cyclosporine-loaded micelles for ocular delivery: investigating the penetration mechanisms
Abstract
Cyclosporine is an immunomodulatory drug commonly used for the treatment of mild-to-severe dry eye syndrome as well as intermediate and posterior segment diseases as uveitis. The ocular administration is however hampered by its relatively high molecular weight and poor permeability across biological barriers. The aim of this work was to identify a micellar formulation with the ability to solubilize a considerable amount of cyclosporine and promote its transport across ocular barriers. Non-ionic amphiphilic polymers used for micelles preparation were tocopherol polyethylene glycol 1000 succinate (TPGS) and Solutol® HS15. Furthermore, the addition of alpha-linolenic acid was assessed. A second aim was to evaluate micelles fate in the ocular tissues (cornea and sclera) to shed light on penetration mechanisms. This was possible by extracting and quantifying both drug and polymer in the tissues, by studying TPGS hydrolysis in a bio-relevant environment and by following micelles penetration with two-photon microscopy. Furthermore, TPGS role as permeation enhancer on the cornea, with possible irreversible modifications of tissue permeability, was analyzed. Results showed that TPGS micelles (approx. 13 nm in size), loaded with 5 mg/ml of cyclosporine, promoted drug retention in both the cornea and the sclera. Data demonstrated that micelles behavior strictly depends on the tissue: micelles disruption occurs in contact with the cornea, while intact micelles diffuse in the interfibrillar pores of the sclera and form a reservoir that can sustain over time drug delivery to the deeper tissues. Finally, cornea quickly restore the barrier properties after TPGS removal from the tissue, demonstrating its potential good tolerability for ocular application.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ghezzi et al. demonstrated that micelles prepared with TPGS and lysosol HS15 decompose upon contact with porcine corneas, damaging the corneal epithelium and promoting penetration and retention of cyclosporine within the cornea.
“Martina Ghezzi et al. demonstrated that micelles prepared with corneal enhancers tocopherol polyethylene glycol 1000 succinate (TPGS) and lysosol ® HS15 decompose upon contact with porcine corneas, damaging the corneal epithelium and thereby promoting the penetration and retention of cyclosporine within the cornea [24].”
From From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics (2025) · cites this paper as [24]
The Conclusion reports that micelles disassemble on contact with the cornea and that TPGS micelles promote cyclosporine retention there. But §3.2.1 says adding Solutol® HS15 decreased delivery efficiency, while the corneal-permeability study (§3.3) found no statistically significant lasting permeability change after TPGS treatment. The paper does not demonstrate that epithelial damage causes the drug uptake; it describes the formulation as having very low irritation potential. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 70 · Cited by 63
- Authors
- Ghezzi, M., Ferraboschi, I., Delledonne, A., Pescina, S., Padula, C., Santi, P., Sissa, C., Terenziani, F., & Nicoli, S.
- Affiliations
- University of Parma (IT)
- Corresponding author
- Nicoli, Sara
- ORCID
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 349
- Pages
- 744-755
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W4288752667
- Cited by
- 63
- References
- 70
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 17 · 2023: 17 · 2022: 5
- FWCI
- 5.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ocular Surface and Contact Lens
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- cyclosporine, ocular drug delivery, micelles, TPGS, Solutol HS15, alpha-linolenic acid, cornea, sclera, corneal barrier, two-photon microscopy, dry eye, uveitis
- MeSH terms
- Cornea, Drug Carriers, Micelles, Polyethylene Glycols, Polymers, Solubility, Succinates, Vitamin E, Cyclosporine, alpha-Linolenic Acid, Tocopherols
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review